Literature DB >> 7890049

Pharmacokinetics of follicle-stimulating hormone: clinical significance.

Z Ben-Rafael1, T Levy, J Schoemaker.   

Abstract

OBJECTIVE: To review studies that examine the pharmacokinetics and pharmacodynamics of endogenous, as well as several exogenous FSH preparations.
DESIGN: Related studies were identified through a computerized bibliographic search. PATIENTS: Initial pharmacodynamic studies were done in animal models and in women and men with either hypogonadotropic hypogonadism or suppressed hypothalamic-pituitary-gonadal axis. More recent studies evaluated FSH pharmacokinetics during ovulation induction treatment in women with normal ovulatory cycles or polycystic ovarian syndrome.
RESULTS: Various types of FSH exist according to their sialic acid content. High estrogen levels induce the secretion of less sialylated molecules with higher receptor affinity and an increased clearance rate. It appears that there is a threshold FSH level that should be reached to achieve an ovarian response. A very narrow range exists between the threshold and ceiling level for monofollicular growth. This threshold level is surpassed intentionally during IVF treatment cycles to induce multiple follicular recruitment. The threshold level can change under situations such as polycystic ovaries, perimenopause, oral contraceptives, and GnRH analogue treatment.
CONCLUSIONS: To avoid the risk of ovarian hyperstimulation syndrome and multiple pregnancies, careful adjustments of serum FSH levels should be made by fine dosage modifications. By monitoring FSH levels and using less sialylated preparations, the efficacy of the treatment probably will improve.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890049     DOI: 10.1016/s0015-0282(16)57467-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

1.  Alcohol, cigarette smoking, and ovarian reserve in reproductive-age African-American women.

Authors:  Leah Hawkins Bressler; Lia A Bernardi; Peter John D De Chavez; Donna D Baird; Mercedes R Carnethon; Erica E Marsh
Journal:  Am J Obstet Gynecol       Date:  2016-07-11       Impact factor: 8.661

2.  Effect of alcohol consumption on in vitro fertilization.

Authors:  Brooke V Rossi; Katharine F Berry; Mark D Hornstein; Daniel W Cramer; Shelley Ehrlich; Stacey A Missmer
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

3.  Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.

Authors:  J Balasch; F Fábregues; M Creus; J Peñarrubia; E Vidal; F Carmona; B Puerto; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  2000-01       Impact factor: 3.412

4.  A successful conception by a shift from human menopausal gonadotropin therapy to therapy with recombinant human follicular-stimulating hormone for the treatment of male hypogonadotropic hypogonadism.

Authors:  Kohei Koyama; Hiroshi Masuda; Teruo Inamoto; Naoki Segawa; Haruhito Azuma; Yoji Katsuoka
Journal:  Reprod Med Biol       Date:  2009-10-06

Review 5.  Alcohol and fertility: how much is too much?

Authors:  Kristin Van Heertum; Brooke Rossi
Journal:  Fertil Res Pract       Date:  2017-07-10

6.  A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol.

Authors:  Yubin Li; Yuwei Duan; Xi Yuan; Bing Cai; Yanwen Xu; Yuan Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-14       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.